US Federal Circuit to hear Myriad breast cancer gene case in July
This article was originally published in Clinica
Executive Summary
The US Court of Appeals for the Federal Circuit will hear oral arguments on 20 July to reconsider its earlier ruling that Myriad Genetics' composition patent claims covering the BRCA1 and BRCA2 genes are valid and that the isolated DNA molecules do not exist in nature.